sumatriptan with naprosyn
PreclinicalSmall molecule
sumatriptan with naprosyn is one of 15 small molecule programs targeting Migraine With Aura. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Migraine With Aura
#DrugCompanyPhaseTrials
1Aleve
Alnylam PharmaceuticalsApproved
Rozerem
TakedaApproved
Marinol
Alnylam PharmaceuticalsApproved
Midamor
PPadagis LLC
Approved
Viagra
VViatris Specialty LLC
Approved
Vivarin
HHikma Pharmaceuticals LLC
Approved
Inderal
WWyeth-Lederle Vaccines
Approved
Atacand
AstraZenecaPhase 2
Sumatriptan Succinate
GSKPhase 2
Tonabersat
IInflammx Therapeutics Inc
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for sumatriptan with naprosyn. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- DDent Neurologic Institute